Should the risk of acquired immunodeficiency syndrome deter hepatitis B vaccination? A decision analysis. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Should the risk of acquired immunodeficiency syndrome deter hepatitis B vaccination? A decision analysis.

JAMA. 1984 Dec 28;252(24):3375-7. Unique Identifier : AIDSLINE MED/85058553
Sacks HS; Rose DN; Chalmers TC

Abstract: The current epidemic of acquired immunodeficiency syndrome (AIDS) and fear that its causative agent contaminates the currently available hepatitis B vaccine may have deterred vaccine use. We formulated a decision-analytic model that compares the risk of death from hepatitis B and AIDS in those vaccinated with the risk of death from hepatitis B alone in those who wait two years for a synthetic vaccine. For individuals with 5% annual risk of hepatitis B, the best current estimate is that vaccination now would save 25 lives per 100,000. The best current estimate of the rate of vaccine-induced AIDS is zero, and one can be 95% confident that the rate is less than eight per 100,000. The rate would have to be considerably higher before postponement of vaccination would be rational for those for whom vaccination has been recommended.
Keywords: Acquired Immunodeficiency Syndrome/MORTALITY/*TRANSMISSION Hepatitis B/EPIDEMIOLOGY/MORTALITY/*PREVENTION & CONTROL Human Risk Support, U.S. Gov't, P.H.S. Time Factors Viral Hepatitis Vaccines/*ADVERSE EFFECTS JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/mortality/KWDtransmissionhepatitisb/epidemiology/mortality/KWDprevention&controlhumanrisksupport,uKWDsKWDgov't,pKWDhKWDsKWDtimefactorsviralhepatitisvaccines/KWDadverseeffectsjournalarticle
850330
M8530083

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .